High risk factors(HRFs) were selected by statistically analyzing the 386 cases of the cervical cancer by radiotherapy at Yonsei University Medical Center (YUMC) from 1976 to 1984.
These risk factors were stage Ⅲ-Ⅳ, small cell carcinoma adenocarcinoma, stage I-Ⅱ and lesion size≥4cm and lymph node metastasis by lymphography.
To evaluate the survuval of patients with at least one of these HRFs following concurrent chemotherapy and to assess the toxicity of concurrent chemotherpay and radiotherapy, 171 patients were selected who at least one of these HRFs from 1984 at
YUMC.
The 54 month survival was 41% with stage Ⅲ-Ⅳ, the 60 month survival was 84% with stage I-Ⅱ and lesion size≥4cm, the 60 month survival was 17% with lymph node metastasis by computed tomography , and the 42 month survival was 43% with small
cell
carcinoma, the 54 month= survival was 72% with adenocarcinoma.
Toxicity of concurrent chemoradiotherapy was mild to moderate degree of leukopenia, anemia. Renal toxicity, thrombocytopenia and hepatotoxicity.
The study's results imply that concurrent chemoradiotherapy may be effective to the Patents with stage Ⅰ-Ⅱ and lesion size≥4cm, and the number of optimal course to significantly improve prognosis while minimizing toxicity need to be
determined.
|